ENTRY       D11757                      Drug
NAME        Inebilizumab (USAN/INN);
            Inebilizumab (genetical recombination) (JAN);
            Inebilizumab-cdon;
            Uplizna (TN)
PRODUCT     UPLIZNA (Horizon Therapeutics USA)
            UPLIZNA (Viela Bio)
FORMULA     C6504H10080N1732O2044S44
EXACT_MASS  146560.5771
MOL_WEIGHT  146650.866
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSWMNWVRQA PGKGLEWVGR IYPGDGDTNY
            NVKFKGRFTI SRDDSKNSLY LQMNSLKTED TAVYYCARSG FITTVRDFDY WGQGTLVTVS
            SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG
            GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
            NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE
            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
            WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            EIVLTQSPDF QSVTPKEKVT ITCRASESVD TFGISFMNWF QQKPDQSPKL LIHEASNQGS
            GVPSRFSGSG SGTDFTLTIN SLEAEDAATY YCQQSKEVPF TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H96, H148-H204, H224-L224, H230-H'230, H265-H325, H371-H429, LH'22-H'96, H'148-H'204, H'224-L'218 H'148-H'204, G'265-H'325, H'371-H'429, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
REMARK      Therapeutic category: 6399
            ATC code: L04AA47
            Product: D11757<JP/US>
EFFICACY    Antineoplastic, Anti-CD19 antibody
  DISEASE   Neuromyelitis optica spectrum disorder (AQP4 antibody positive) [DS:H01491]
  TYPE      Monoclonal antibody
COMMENT     Treatment of cancer, systemic sclerosis, and multiple sclerosis
TARGET      CD19 [HSA:930] [KO:K06465]
  PATHWAY   hsa04151(930)  PI3K-Akt signaling pathway
            hsa04640(930)  Hematopoietic cell lineage
            hsa04662(930)  B cell receptor signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA47 Inebilizumab
                  D11757  Inebilizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Ophthalmic Agents, Monoclonal Antibodies
                Inebilizumab
                 D11757  Inebilizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D11757  Inebilizumab (USAN/INN); Inebilizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD19
                 D11757  Inebilizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11757
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11757
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11757
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11757
DBLINKS     CAS: 1299440-37-1
            PubChem: 405226623
///
